Last reviewed · How we verify
NCT06265870: Eosinophilia
Specific Versus Empirical Anthelminthic Treatment in Eosinophilia
NA trial testing Albendazole in Eosinophilia in 700 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Prince of Songkla University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 700 |
| Start date | 1 May 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Albendazole (ALBENDAZOLE) — full drug profile →
- Ivermectin or albendazole — full drug profile →
Conditions studied
- Eosinophilia — all drugs for Eosinophilia →
Sponsor
Prince of Songkla University
Who can join
18 and older, any sex, with Eosinophilia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06265870
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Albendazole
Trials testing the same drug.
- NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting
- NCT04713787 — A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuri · Phase 2 · recruiting
- NCT06483880 — The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection · NA · unknown
- NCT05453045 — Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva · NA · unknown
- NCT05124691 — Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms · Phase 2, PHASE3 · terminated
Other recruiting trials for Eosinophilia
Currently open trials in the same condition.
- NCT05942222 — A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis Wit · Phase 4 · active not recruiting
- NCT03801434 — Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders · Phase 2 · recruiting
- NCT00091871 — A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression · recruiting
- NCT00001406 — Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia · recruiting
Other Prince of Songkla University trials
Trials by the same sponsor.
- NCT06841133 — Chinese Art Activities or Combined With Peer Group Participation on Psychological Well Being · NA · not yet recruiting
- NCT06837116 — Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers · EARLY_PHASE1 · completed
- NCT06476652 — Effect of Simple Simulator-based Training on Initial Performance of Novices Iultrasound-guided Adductor Canal Block · enrolling by invitation
- NCT07245966 — Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis · completed
- NCT06219525 — Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06265870 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prince of Songkla University
- Last refreshed: 24 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06265870.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing